Pre-exposure prophylaxis for HIV: Difference between revisions

From IDWiki
(updated to match Canadian guidelines)
(No difference)

Revision as of 05:30, 24 September 2020

  • Principle: give HIV meds to high-risk individuals to prevent seroconversion if exposed
  • Works when adherent, but adherence is poor

Eligibility

  • MSM: condomless anal sex within the last 6 months, and any of:
    • Sexually transmitted infection within the last 12 months
    • Recurrent use of HIV PEP at least twice
    • Ongoing sexual relationship with an HIV-positive partner who has a detectable viral load or is not on treatment
      • Stop if partner is undetectable for 6 months
    • High-incidence risk index (HIRI)-MSM ≥11
  • Heterosexual exposure
    • Ongoing condomless sexual relationship with an HIV-positive partner who has a detectable viral load or is not on treatment
      • Stop if partner is undetectable for 6 months
    • Can be considered even if condomless sexual relationship with an HIV-positive partner with low risk
  • People who inject drugs
    • Consider if they share drug paraphernalia with someone who has risk of HIV
    • People who inject drugs may not benefit as much

Process

Baseline

Treatment

  • Tenofovir disoproxil fumarate/emtricitabine 300/200 mg daily for 3 months at a time, without repeats
  • Counsel on condom use and side effects
    • Take it for 7 days before it is effective
    • Connect to mental health and other services, if indicated

Follow-up

  • Follow-up after 30 days and then every 3 months thereafter
Item Baseline 30 days q3mo q12mo
Clinical Evaluation
Symptoms of HIV seroconverion x x x
PrEP adherence and side effects x x
Assess indication for PrEP x x x
Counsel on prevention of HIV and STIs x x x
Assess and manage other syndemic conditions, including drug and alcohol use x x x
Laboratory Evaluation
HIV test x x x
Hepatitis A immunity x
Hepatitis B screen x if unvaccinated
Hepatitis C screen x
Screen for gonorrhea and chlamydia x x
Syphilis serology x x
CBC x x
Creatinine x x x
Urinalysis x
Pregnancy test (if appropriate) x x

Further Reading

  • Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ 2017;189(47):e1448-e1458. doi: 10.1503/cmaj.170494